TLC-6740

1. TLC-6740 decreases MRI proton density fat fraction in humans (-60.6% vs -44.0% (p=0.12)).

   “Among participants with BL liver fat ≥5% (MASLD), MRI-PDFF decreased -60.6% with TLC-6740 (n=13) vs -44.0% with placebo (n=7; p=0.12).”

   Human trialcombination with tirzepatide in adults with obesity and baseline liver fat >=5%180 mg daily oral24 weeks

   Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on MRI proton density fat fraction

1. TLC-6740 decreases visceral adipose tissue in humans (-24.8% vs -15.9% (p=0.052)).

   “TZP plus TLC-6740 (n=25) vs TZP plus placebo (n=12) produced greater reductions in visceral adipose tissue (-24.8% vs -15.9%; p=0.052)”

   Human trialcombination with tirzepatide in adults with obesity180 mg daily oral24 weeks

   Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. TLC-6740 decreases body weight in humans (-13.3% vs -8.8% (additional 4.5% weight loss, p=0.018)).

   “At W24, mean weight change was -8.8% with TZP plus placebo and -13.3% with TZP plus TLC-6740, an additional 4.5% weight loss with the combination (p=0.018, ITT)”

   Human trialcombination with tirzepatide in adults with obesity180 mg daily oral24 weeksn = 55

   Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study

   ADA Scientific Sessions 2026 abstract·5 Jun 2026